QX for sales quarter product Abecma in growth of first Abecma, the over XXX% over year. $XXX growth strong for which was a the robust XX% same Nick. another and quarter, the quarter Thanks, increase million the were demand U.S. prior the last for reflecting represents continued quarter
end million we $XXX and gives us confidence of share best losses revenue track guidance. the million on $XXX in As and equally United and upper to a Abecma's are date all reminder, of in BMS the was States. Abecma to of achieve our quarter profits This U.S. we to that
our space. underappreciated Underpinning CAR platform of the in T is best commercial most the operations and one manufacturing
high is XX-day rates range. the in our XX% consistently achieve in and continue the We manufacturing to range, in-spec turnaround time
we this important progress made quarter addition, expanding capacity. In manufacturing our
suite, on introduction we which terms we're vector the for to vector, regulatory increases first a continued file of BMS commercial approval to suspension also XXXX. of having later FDA part goal use of year, and track the suspension-based adherent accelerate and approved in Specifically, in vector approval of with for for the significantly vector our Xseventy this capacity, received second capacity. vector
announced which potential long-term and also Illinois shared the product. for our suspension agreement BMS in belief the a in-house, capacity of manufacturing in facility signals an to produce increases vector
on a we additional in track completed for this later successful year. On product capacity ramps side, drug and step-up the are
quarter. progress made important clinical and also We from regulatory perspective this a
December to expand Our thousands was for leading here PDUFA sBLA label, for -- patients a United on reaching date. the the KarMMa-X Approval States. accepted would in filing the potentially with more study
can while we several expect market the the terms of landscape, continues remain patients, a in setting. provide news look third-line we a is of competitive supply-constrained comprehensive the products field rapidly real-world commercial for which with to view medical evolve And performing approval, We the to more are supply-constrained And to the in come. great upcoming are evidence market meetings, for in to today. years forward how where
the in forward we nature the in the to high-risk trials. Additionally, patient difference highlighting clinical of look population treated our
facts to myeloma. like to I'd Nick's multiple in of add additional are that point belief behind potential future belief context three our Abecma. our Finally, some Abecma a in treating about the long-term has long-term There important earlier
and takes time. depends regulators. and the manufacturing T CAR it scale-up also First, It on complex training frankly, hiring just is and governed operators in by suites significant the linear, of
supply-constrained industry, an be years. for will As we
never-been-seen-before There's high in market. not with newly growth simply multiple medical service U.S., capacity competitors, there's also Even any unmet from in XX,XXX patients the year. capacity a need one for to the myeloma each enough with diagnosed sponsor optimistic, in
beyond physicians setting, treatment the and role seeing turnaround on factors reported and we commercial that play depend and a time patients clinical finally, play inspect CAR large decisions Safety, And by out. rates, T are in efficacy. execution all
significantly grow. on the cash Shifting and remain gears million quarter contribution to of the this sheet to quarter, we and to expect first with Abecma quarter and equivalents. balance track Xseventy financials. We cash position positive We Abecma from to continue flow was year strong is in cash ended of $XXX a budget million $XXX will towards spend last a for as on we reiterate coming the is decrease This continue down that breakeven and to years. our cash our XXXX. $XXX number from to with we expenses, flow net guidance move and million cash in
turn now, in to highlights. Q&A. take questions we'll for I'm the it But for R&D some happy to Philip over Philip?
